Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Fosamax once-weekly patent upheld

Executive Summary

Merck Fosamax once-weekly dose will not face generic competition until 2019, under a ruling by the Wilmington, Del. federal court to uphold a method of use patent (no. 5,994,329) for the 35 mg and 70 mg strengths of the osteoporosis agent. Teva plans to appeal the decision; the company is also awaiting a ruling on its appeal of the same court's decision to uphold Merck's method of use patent covering the Fosamax (alendronate) once-daily products (1"The Pink Sheet" Nov. 11, 2002, In Brief)...
Advertisement

Related Content

Merck Fosamax patent upheld
Advertisement
UsernamePublicRestriction

Register

PS042397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel